BOLD
RESEARCH

Dr. Zoda brings nearly 30 years of clinical research industry experience to CRC. Most of his career has been dedicated to the CNS clinical research space through a variety of roles in operations, business development, and executive leadership. Notably, Dr. Zoda was the Executive Vice President and General Manager for the CNS Business Unit at INC Research/Syneos Health during their exponential growth over the last decade. Prior, he enjoyed a long tenure at PPD in a variety of operations and executive roles. Most recently, Dr. Zoda served as COO for Apex Innovative Sciences and CenExel Clinical Research, both CNS-focused clinical research site networks.

Dr. Hochadel has more than 30 years of experience planning, managing, and conducting clinical research trials. His Phase I work includes multiple-dose studies in healthy elderly subjects, tyramine challenge pressor tests, and evaluations of transdermal, nasal, and pulmonary delivery systems. Each program included detailed pharmacokinetic and wearability assessments that advanced CNS study methodology.

His Phase II–IV development expertise is demonstrated through dementia studies, including 48-week chronic dosing research in Alzheimer’s disease and nursing-home trials targeting behavioral symptoms. Experience also extends to schizophrenia, Parkinson’s disease, ataxia, tardive dyskinesia, depression, bipolar disorder, ADHD, OCD, and sleep-disorder programs. In addition, he directed an anti-osteoporosis compound IND and a full development program.

As one of CRC’s original founders in 2006, Dr. Hochadel initially served as Chief Operating Officer. His reputation for integrity and CNS expertise attracted early clients—many who still partner with the company today. A focus on team building and transparent collaboration established CRC’s culture and performance standards. He continues to lead the company as President.

Before CRC, he served as Senior Director of Psychiatry and Neurology at SCIREX Corporation and as Director of Clinical Operations (CNS Center) at Covance, Inc. In those roles, he guided senior project managers and cross-functional teams overseeing all clinical aspects of CNS studies. Earlier, he spent six years at Somerset Pharmaceuticals, developing preclinical-to-post-marketing plans and regulatory submissions.

While at Somerset, Dr. Hochadel conducted more than 30 Phase I clinical studies and led multiple IND applications. He later became President of Advanced Research Corporation, where he managed the organization’s overall operations and financial performance as a full-service contract research company.

A graduate of Mercer University’s Southern School of Pharmacy in Atlanta, Georgia, he earned his Pharm.D. and completed a B.S. in Natural Sciences from the University of South Florida. He is a registered pharmacist and actively participates in international medical missions.

Dr. Kay is the co-founder and Chief Scientific Officer of Cognitive Research Corporation. He brings decades of experience in neuropsychology and clinical research.

They earned a Ph.D. in psychology (neuro-clinical specialty program) from the University of Memphis. His psychology internship took place at the National Naval Medical Center in Bethesda, Maryland.

From 1985 to 1998, he directed the Neuropsychology Division in Georgetown University’s Department of Neurology. His work included teaching, clinical services, and research. He developed computerized methods to assess higher cortical functions. He also studied how conditions such as HIV, head injury, fibromyalgia, diabetes, and alcoholism affect cognition and aging.

Kay authored and published CogScreen, a computerized cognitive test battery widely used in research and clinical settings. He is recognized internationally for using driving simulation to study how medications affect driving performance.

In 1998, he founded the Washington Neuropsychological Institute. The firm conducted contract research and advised federal agencies including the FAA, Department of Justice, and Social Security Administration.

He served as Principal Investigator on single- and multi-center drug trials that explored how medications affect cognition and mood. His studies examined treatments such as sedating antihistamines, hormone therapy, stimulant medications, anticholinergics, and nutritional supplements.

As an internationally recognized speaker, Kay has presented at professional meetings around the world. He contributed to the work of the National Academy of Sciences. His expertise also led to testimony before congressional committees and FDA hearings. He has consulted for many governmental, corporate, and medical organizations.

Kay co-authored Aeromedical Psychology and wrote several book chapters. His research appears in Archives of Internal Medicine, American Psychologist, Human Psychopharmacology, British Journal of Pharmacology, Aviation, Space and Environmental Medicine, Annals of Allergy, and the American Journal of Managed Care.

He is a diplomate of the American Board of Professional Neuropsychology and the American Board of Assessment Psychology. Kay serves as an Associate Professor of Neurology at Georgetown University. He is also a Fellow of the National Academy of Neuropsychologists and an active member of both the International Neuropsychological Society and the American Psychological Association.